生物模擬市場規模、份額、趨勢分析報告產品（軟件、服務）、應用（藥物開發、藥物發現）、最終應用、地區、細分預測，2022-2030

生物模擬市場的增長和趨勢

根據 Grand View Research, Inc. 的一份新報告，預計到 2030 年，全球生物模擬市場規模將達到 99.5 億美元。

從 2022 年到 2030 年，市場預計將以 16.9% 的複合年增長率增長。市場增長的關鍵因素包括慢性病發病率的增加、醫療保健數字化程度的提高以及生物模擬解決方案在臨床試驗和研究中的使用。

隨著急慢性疾病的流行，藥物發現開發的需求增加，研發活動的資金分配增加，生物模擬解決方案的採用得到促進。此外，由於藥物減量率高導致臨床試驗成本增加，預計採用計算機生物學方法將增加臨床試驗的緊迫性。這種方法可以通過預測生物相互作用來顯著降低藥物失敗的可能性並降低總體成本。

由於藥物復發率的增加、耐藥病例的增加以及治療艾滋病等疾病的藥物供應受到限制，臨床上可以將生物模擬應用於藥物開發和藥物發現等應用。它的要求越來越高。

COVID-19 大流行也對市場增長產生了重大影響。例如，Simulations Plus 於 2020 年 3 月啟動了 Strategies Plus COVID-19 ACT 計劃，以加快向所有參與 COVID-19 研究的組織提供諮詢援助。截至 2020 年 11 月，公司已宣布不會對其業務產生重大負面影響。但是，COVID-19 的持續擴張以及受影響國家政府採取的措施可能會擾亂供應鏈並對公司的業務和財務狀況產生不利影響。

對生物模擬軟件和服務的需求不斷增長，也是由於其高成本效益。生物模擬解決方案可以在產品開發的早期經濟有效地預測研究藥物的毒性、副作用和療效，降低後期藥物復發和不良事件的概率。

市場參與者正在投資於許多戰略舉措，例如收購、合併、合作夥伴關係和產品發布，以保持市場競爭力。例如，2022 年 1 月，Simulations Plus Inc. 與一家獸醫公司合作，驗證當前的動物生理藥代動力學 (PBPK) 模型。通過這項資助合作，該公司尋求在 GastroPlus 平台上添加一個重要的新物種。此外，2021年11月，橫河電機有限公司收購了德國Insilico Biotechnology AG，該公司開發和提供生物工藝軟件和服務。

生物模擬市場報告亮點

• 按產品劃分，軟件在 2021 年佔據市場主導地位。這可能是由於滿足研究要求的各種特定應用軟件的可用性。此外，生物模擬軟件用於臨床試驗，以促進建模和目標藥物識別。
• 2021 年，藥物開發使用部分的收入份額將超過 55.0%。
• 由於戰略計劃的增加，製藥和生物技術公司的最終用途將在 2021 年佔據最大的收入份額。
• 2021 年，北美收入佔比最高，超過 45.0%。有利的醫療費用框架（特別是在實施《健康保險改革法案》之後）和先進的醫療基礎設施的存在預計將在預測期內推動該地區的市場。
• 由於 CRO 數量增加、醫療保健 IT 支出增加以及醫療保健基礎設施快速發展，預計亞太地區將在預測期內顯著增長。

目錄

第 1 章調查方法及範圍

• 市場細分和範圍
  • 細分範圍
  • 區域範圍
  • 時間線估計/預測
• 調查方法
• 資訊採購
  • 購買的數據庫：
  • GVR 內部數據庫
  • 二次材料
  • 初步調查
  • 初步調查詳情
• 資訊或數據分析
  • 數據分析模型
• 市場製定與驗證
• 型號詳情
• 二次材料清單
• 目的
  • 目的 1
  • 目的 2
  • 目的 3
  • 目的 4

第 2 章執行摘要

• 生物模擬市場概況

第 3 章生物模擬市場的變量、趨勢和範圍

• 生物模擬市場細分和範圍
• 生物模擬市場動態
  • 市場促進因素分析
  • 影響分析
    • 在藥品監管審批流程中越來越多地採用基於生理學的藥代動力學模型
    • 耐藥性增加導致復發病例增加
    • 不斷進步的技術進步
    • 越來越需要降低藥物發現和開發成本
    • 加快配方開發並節省昂貴的研究費用
    • 增加對生命科學行業的投資
    • 增加使用個性化醫療
  • 市場資訊分析
  • 影響分析
    • 缺乏標準化
    • 缺乏熟練的專業人員
    • 知識產權保護和公共政策問題
• 2021 年滲透率和增長前景圖
• 價格分析
• 生物模擬市場分析工具：Porter
  • 供應商議價能力：低
  • 買方議價能力：中等
  • 替代治療：低
  • 新進入者的威脅：高
  • 競爭對手之間的敵對關係：高
• 基於因素的 SWOT 分析（政治和法律、經濟和技術）
  • 政治/法律狀況
  • 經濟形勢
  • 技術情況

第 4 章生物模擬市場：COVID-19 的影響

• COVID-19 對生物模擬市場的影響
  • 當前和未來的影響分析
  • COVID-19 對市場參與者的影響
  • 疾病流行分析

第 5 章生物模擬市場：細分分析，產品，2017-2030

• 定義和範圍
• 2021 年和 2030 年產品市場份額分析
• 2017-2030 年生物模擬市場，按產品分類
• 軟件
  • 2017-2030 年軟件市場
• 服務
  • 2017-2030年服務市場
  • 內部服務
    • 2017-2030年內部服務市場
  • 合同服務
    • 2017-2030 年合同服務市場

第 6 章生物模擬市場：細分分析，按應用，2017-2030

• 定義和範圍
• 2021 年和 2030 年應用市場份額分析
• 生物模擬市場，按應用，2017-2030
• 藥物開發
  • 2017-2030年藥物開發市場
• 藥物發現
  • 2017-2030 年藥物發現市場
• 其他
  • 其他市場，2017-2030

第 7 章生物模擬市場：細分分析，按最終用途，2017-2030

• 定義和範圍
• 2021 年和 2030 年最終用途市場份額分析
• 2017-2030 年全球生物模擬市場，按最終用途分類
• 製藥和生物技術公司
  • 2017-2030年醫藥及生物科技企業市場
• CRO
  • 2017-2030 年 CRO 市場
• 調節器
  • 監管市場，2017-2030
• 學術研究所
  • 2017-2030 年學術研究機構市場

第 8 章生物模擬市場：2017-2030 年區域市場分析

• 定義和範圍
• 2021 年和 2030 年區域市場份額分析
• 區域市場概況
• 2017-2030 年市場規模、預測和趨勢分析
• 北美
  • 2021 年按國家/地區分列的北美生物模擬市場份額分析
  • 美國
    • 2017-2030年美國生物模擬市場
  • 加拿大
    • 2017-2030 年加拿大生物模擬市場
• 歐洲
  • 2021 年歐洲生物模擬市場份額分析，按國家/地區分列
  • 英國
    • 2017-2030 年英國生物模擬市場
  • 德國
    • 2017-2030 年德國生物仿真市場
  • 法國
    • 2017-2030 年法國生物模擬市場
• 亞太地區
  • 亞太地區生物模擬市場份額分析，國家，2021
  • 日本
    • 2017-2030年日本生物仿真市場
  • 中國
    • 2017-2030年中國生物模擬市場
  • 印度
    • 印度生物模擬市場，2017-2030
• 拉丁美洲
  • 拉丁美洲生物模擬市場份額分析，國家，2021
  • 巴西
    • 2017-2030 年巴西生物模擬市場
  • 墨西哥
    • 2017-2030 年墨西哥生物模擬市場
• 多邊環境協定
  • MEA 生物模擬市場份額分析，國家，2021
  • 南非
    • 2017-2030 年南非生物模擬市場

第 9 章生物仿真市場-競爭分析

• 戰略框架
• 市場參與者的分類
• 上市公司
  • 公司市場分析
  • 產品類別對比分析
• 私人公司
  • 私營公司名單
  • 亞太區初創企業名單

第 10 章生物模擬市場-公司簡介

• Certara, USA
  • 公司簡介
  • 財務表現
  • 產品基準
  • 戰略舉措
• Simulations Plus
  • 公司簡介
  • 財務表現
  • 產品基準
  • 戰略舉措
• Dassault Systemes
  • 公司簡介
  • 財務表現
  • 產品基準
  • 戰略舉措
• Schrodinger, Inc.
  • 公司簡介
  • 財務表現
  • 產品基準
  • 戰略舉措
• Advanced Chemistry Development
  • 公司簡介
  • 產品基準
  • 戰略舉措
• Chemical Computing Group ULC
  • 公司簡介
  • 財務表現
  • 產品基準
  • 戰略舉措
• Physiomics Plc
  • 公司簡介
  • 財務表現
  • 產品基準
  • 戰略舉措
• Rosa & Co. LLC
  • 公司簡介
  • 產品基準
  • 戰略舉措
• Biosimulation Consulting Inc.
  • 公司簡介
  • 財務表現
  • 服務基準
• Genedata AG
  • 公司簡介
  • 財務表現
  • 產品基準
  • 戰略舉措
• Instem Group of Companies
  • 公司簡介
  • 財務表現
  • 產品基準
  • 戰略舉措
• PPD, Inc.
  • 公司簡介
  • 財務表現
  • 服務基準
  • 戰略舉措
• Yokogawa Insilico Biotechnology GmbH
  • 公司簡介
  • 產品基準
  • 戰略舉措
• Immunetrics
  • 公司簡介
  • 產品基準

第11章KOL評論

Biosimulation Market Growth & Trends:

The global biosimulation market size is expected to reach USD 9.95 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 16.9% from 2022 to 2030. The key factors fueling the market growth include the increasing incidence of chronic diseases, increase in healthcare digitization, and usage of biosimulation solutions in clinical trials and research.

The need for drug discovery and development amidst the prevalence of acute and chronic diseases has increased the allocation of funds for R&D activities, which has propelled the adoption of biosimulation solutions. In addition, a high drug attrition rate leads to an increase in the cost of clinical trials, which is expected to drive the clinical urgency to incorporate in silico biology approach. This approach significantly reduces the probability of drug failure by predicting biological interactions, thereby reducing overall costs.

A rise in drug relapse rates, drug resistance cases, and the limited availability of drugs to treat diseases such as AIDS have led to high clinical urgency for the adoption of biosimulation in applications such as drug development and drug discovery.

The COVID-19 pandemic also had a significant impact on the market growth. Simulations Plus, for instance, launched the StrategiesPlus COVID-19 ACT Program in March 2020 for speeding consulting assistance to any organization involved in COVID-19 research. The company declared that as of November 2020, its business was not materially adversely affected. However, the continuing spread of COVID-19 and the measures taken by governments of affected countries are likely to disrupt the supply chain and adversely impact its business and financial performance.

Surging demand for biosimulation software and services can also be attributed to their higher cost-efficiency. Biosimulation solutions enable cost-effective prediction of toxicity, adverse reactions, and efficacy of investigational drugs during the early stages of product development, thus limiting the probability of drug relapse and adverse events at later stages.

Market players are investing in many strategic initiatives, such as acquisitions, mergers, partnerships, and product launches, to maintain a competitive edge in the market. For instance, in January 2022, Simulations Plus Inc. collaborated with an animal health company for validating current animal physiologically based pharmacokinetic (PBPK) models. With this funded collaboration, the company aimed to add a critical new species to its GastroPlus platform. Moreover, in November 2021, Yokogawa Electric Corporation acquired Insilico Biotechnology AG, a Germany-based company that develops and provides bioprocess software and services.

Biosimulation Market Report Highlights:

• By product, software dominated the market in 2021. This can be attributed to the availability of a wide range of application-specific software that suits research requirements. Furthermore, biosimulation software is being used in clinical trials and it also eases modeling and targets drug identification

• The drug development application segment accounted for the largest revenue share of more than 55.0% in 2021

• By end-use, pharmaceutical and biotechnology companies held the largest revenue share in 2021 due to the increasing strategic initiatives

• North America grabbed the largest revenue share of over 45.0% in 2021. The presence of a favorable reimbursement framework (especially post the implementation of the Affordable Care Act) and sophisticated healthcare infrastructure are expected to drive the regional market over the forecast period

• The Asia Pacific region is expected to grow significantly during the forecast period owing to the increase in the number of CROs, growth in spending on healthcare IT, and rapidly evolving healthcare infrastructure

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation and Scope
  • 1.1.1 segment scope
  • 1.1.2 regional scope
  • 1.1.3 Estimates and forecast timeline
• 1.2 Research Methodology
• 1.3 Information procurement
  • 1.3.1 Purchased database:
  • 1.3.2 GVR's internal database
  • 1.3.3 Secondary sources
  • 1.3.4 Primary research
  • 1.3.5 Details of primary research
• 1.4 Information or Data Analysis
  • 1.4.1 Data analysis models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
• 1.7 List of Secondary Sources
• 1.8 Objectives
  • 1.8.1 Objective 1
  • 1.8.2 Objective 2
  • 1.8.3 Objective 3
  • 1.8.4 Objective 4

Chapter 2 Executive Summary

• 2.1 Biosimulation Market Summary

Chapter 3 Biosimulation Market Variables, Trends & Scope

• 3.1 Biosimulation Market Segmentation and Scope
• 3.2 Biosimulation Market Dynamics
  • 3.2.1 Market driver analysis
  • 3.2.2 Impact analysis
    • 3.2.2.1 Increasing adoption of Physiologically Based Pharmacokinetic Modeling in the regulatory approval process of drugs
    • 3.2.2.2 Growing number of relapse cases due to increasing drug resistance
    • 3.2.2.3 Rising Technological advancements
    • 3.2.2.4 Increasing need to reduce drug discovery and development costs
    • 3.2.2.5 accelerating formulation development and saving costly studies
    • 3.2.2.6 Increasing investments in the life sciences industry
    • 3.2.2.7 Increasing use of personalized medicine
  • 3.2.3 Market restraint analysis
  • 3.2.4 Impact analysis
    • 3.2.4.1 Lack of standardization
    • 3.2.4.2 Shortage of skilled professionals
    • 3.2.4.3 Intellectual property protection and public policy issues
• 3.3 Penetration and Growth Prospect Mapping, 2021
• 3.4 Pricing Analysis
• 3.5 Biosimulation Market Analysis Tools: Porters
  • 3.5.1 bargaining power of Suppliers: Low
  • 3.5.2 bargaining power of Buyers: Moderate
  • 3.5.3 Therat of Substitutes: Low
  • 3.5.4 Threat of New Entrants: High
  • 3.5.5 Competitive Rivalry: High
• 3.6 SWOT Analysis by Factors (Political & Legal, Economic, and Technological)
  • 3.6.1 Political/Legal Landscape
  • 3.6.2 Economic Landscape
  • 3.6.3 Technology Landscape

Chapter 4 Biosimulation Market: Impact of COVID-19

• 4.1 Impact of Covid-19 on the Biosimulation Market
  • 4.1.1 Current And Future Impact Analysis
  • 4.1.2 Impact of covid-19 on market players
  • 4.1.3 Disease Prevalence Analysis

Chapter 5 Biosimulation Market: Segment Analysis, By Product, 2017 - 2030 (USD Million)

• 5.1 Definition and Scope
• 5.2 Product Market Share Analysis, 2021 & 2030
• 5.3 Biosimulation Market, by Product, 2017 - 2030
• 5.4 Software
  • 5.4.1 software market, 2017 - 2030 (USD Million)
• 5.5 Services
  • 5.5.1 Services market, 2017 - 2030 (USD Million)
  • 5.5.2 In-house Services
    • 5.5.2.1 In-house Services market, 2017 - 2030 (USD Million)
  • 5.5.3 Contract Services
    • 5.5.3.1 Contract Services market, 2017 - 2030 (USD Million)

Chapter 6 Biosimulation Market: Segment Analysis, By Application, 2017 - 2030 (USD Million)

• 6.1 Definition and Scope
• 6.2 Application Market Share Analysis, 2021 & 2030
• 6.3 Biosimulation Market, by Application, 2017 - 2030
• 6.4 Drug Development
  • 6.4.1 drug development market, 2017 - 2030 (USD Million)
• 6.5 Drug Discovery
  • 6.5.1 Drug Discovery market, 2017 - 2030 (USD Million)
• 6.6 Others
  • 6.6.1 Others market, 2017 - 2030 (USD Million)

Chapter 7 Biosimulation Market: Segment Analysis, By End-use, 2017 - 2030 (USD Million)

• 7.1 Definition and Scope
• 7.2 End-use Market Share Analysis, 2021 & 2030
• 7.3 Global Biosimulation Market, by End-use, 2017 - 2030
• 7.4 Pharmaceutical & Biotechnology Companies
  • 7.4.1 Pharmaceutical & biotechnology companies market, 2017 - 2030 (USD Million)
• 7.5 CROs
  • 7.5.1 CROs market, 2017 - 2030 (USD million)
• 7.6 Regulatory Authorities
  • 7.6.1 Regulatory authorities market, 2017 - 2030 (USD Million)
• 7.7 Academic Research Institutions
  • 7.7.1 Academic research institutions market, 2017 - 2030 (USD million)

Chapter 8 Biosimulation Market: Regional Market Analysis 2017 - 2030 (USD Million)

• 8.1 Definition & Scope
• 8.2 Regional Market Share Analysis, 2021 & 2030
• 8.3 Regional Market Snapshot
• 8.4 Market Size, & Forecasts, and Trend Analysis, 2017 - 2030
• 8.5 North America
  • 8.5.1 North America Biosimulation Market Share Analysis, By Country, 2021
  • 8.5.2 U.S.
    • 8.5.2.1 U.S. Biosimulation Market, 2017 - 2030 (USD Million)
  • 8.5.3 Canada
    • 8.5.3.1 Canada Biosimulation Market, 2017 - 2030 (USD Million)
• 8.6 Europe
  • 8.6.1 Europe Biosimulation Market Share Analysis, By Country, 2021
  • 8.6.2 U.K.
    • 8.6.2.1 U.K. Biosimulation Market, 2017 - 2030 (USD Million)
  • 8.6.3 Germany
    • 8.6.3.1 Germany Biosimulation Market, 2017 - 2030 (USD Million)
  • 8.6.4 France
    • 8.6.4.1 France Biosimulation Market, 2017 - 2030 (USD Million)
• 8.7 Asia Pacific
  • 8.7.1 Asia Pacific Biosimulation Market Share Analysis, By Country, 2021
  • 8.7.2 Japan
    • 8.7.2.1 Japan Biosimulation Market, 2017 - 2030 (USD Million)
  • 8.7.3 China
    • 8.7.3.1 China Biosimulation Market, 2017 - 2030 (USD million)
  • 8.7.4 India
    • 8.7.4.1 India Biosimulation Market, 2017 - 2030 (USD Million)
• 8.8 Latin America
  • 8.8.1 Latin America Biosimulation Market Share Analysis, By Country, 2021
  • 8.8.2 Brazil
    • 8.8.2.1 Brazil Biosimulation Market, 2017 - 2030 (USD Million)
  • 8.8.3 Mexico
    • 8.8.3.1 Mexico Biosimulation Market, 2017 - 2030 (USD Million)
• 8.9 MEA
  • 8.9.1 MEA Biosimulation Market Share Analysis, By Country, 2021
  • 8.9.2 South Africa
    • 8.9.2.1 South Africa Biosimulation Market, 2017 - 2030 (USD Million)

Chapter 9 Biosimulation Market - Competitive Analysis

• 9.1 Strategy Framework
• 9.2 Market Participant Categorization
• 9.3 Public Companies
  • 9.3.1 Company market position analysis
  • 9.3.2 Comparative analysis by product category
• 9.4 Private Companies
  • 9.4.1 List of Private companies
  • 9.4.2 List of Emerging companies in the Asia Pacific Region

Chapter 10 Biosimulation Market - Company Profiles

• 10.1 Certara, USA
  • 10.1.1 Company overview
  • 10.1.2 Financial performance
  • 10.1.3 Product benchmarking
  • 10.1.4 Strategic initiatives
• 10.2 Simulations Plus
  • 10.2.1 Company overview
  • 10.2.2 Financial performance
  • 10.2.3 Product benchmarking
  • 10.2.4 Strategic initiatives
• 10.3 Dassault Systemes
  • 10.3.1 Company overview
  • 10.3.2 Financial performance
  • 10.3.3 Product benchmarking
  • 10.3.4 Strategic initiatives
• 10.4 Schrodinger, Inc.
  • 10.4.1 Company overview
  • 10.4.2 Financial performance
  • 10.4.3 Product benchmarking
  • 10.4.4 Strategic initiatives
• 10.5 Advanced Chemistry Development
  • 10.5.1 Company overview
  • 10.5.2 Product benchmarking
  • 10.5.3 Strategic initiatives
• 10.6 Chemical Computing Group ULC
  • 10.6.1 Company overview
  • 10.6.2 Financial performance
  • 10.6.3 Product benchmarking
  • 10.6.4 Strategic initiatives
• 10.7 Physiomics Plc
  • 10.7.1 Company overview
  • 10.7.2 Financial performance
  • 10.7.3 Product benchmarking
  • 10.7.4 Strategic initiatives
• 10.8 Rosa & Co. LLC
  • 10.8.1 Company overview
  • 10.8.2 Product benchmarking
  • 10.8.3 Strategic initiatives
• 10.9 Biosimulation Consulting Inc.
  • 10.9.1 Company overview
  • 10.9.2 Financial performance
  • 10.9.3 Service benchmarking
• 10.10 Genedata AG
  • 10.10.1 Company overview
  • 10.10.2 Financial performance
  • 10.10.3 Product benchmarking
  • 10.10.4 Strategic initiatives
• 10.11 Instem Group of Companies
  • 10.11.1 Company overview
  • 10.11.2 Financial performance
  • 10.11.3 Product benchmarking
  • 10.11.4 Strategic initiatives
• 10.12 PPD, Inc.
  • 10.12.1 Company overview
  • 10.12.2 Financial performance
  • 10.12.3 Service benchmarking
  • 10.12.4 Strategic initiatives
• 10.13 Yokogawa Insilico Biotechnology GmbH
  • 10.13.1 Company overview
  • 10.13.2 Product benchmarking
  • 10.13.3 Strategic initiatives
• 10.14 Immunetrics
  • 10.14.1 Company overview
  • 10.14.2 Product benchmarking

Chapter 11 KOL Commentary

List of Tables

• Table 1 List of secondary sources
• Table 2 List of products for major companies
• Table 3 List of private companies
• Table 4 List of emerging companies
• Table 5 North America biosimulation market, by country, 2017 - 2030 (USD Million)
• Table 6 North America biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 7 North America biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 8 North America biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 9 North America biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 10 U.S. biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 11 U.S. biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 12 U.S. biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 13 U.S. biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 14 Canada biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 15 Canada biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 16 Canada biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 17 Canada biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 18 Europe biosimulation market, by country, 2017 - 2030 (USD Million)
• Table 19 Europe biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 20 Europe biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 21 Europe biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 22 Europe biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 23 Germany biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 24 Germany biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 25 Germany biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 26 Germany biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 27 U.K. biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 28 U.K. biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 29 U.K. biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 30 U.K. biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 31 France biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 32 France biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 33 France biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 34 France biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 35 Asia Pacific biosimulation market, by country, 2017 - 2030 (USD Million)
• Table 36 Asia Pacific biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 37 Asia Pacific biosimulation services market, by type, 2017 - 2030(USD Million)
• Table 38 Asia Pacific biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 39 Asia Pacific biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 40 Japan biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 41 Japan biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 42 Japan biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 43 Japan biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 44 China biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 45 China biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 46 China biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 47 China biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 48 India biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 49 India biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 50 India biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 51 India biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 52 Latin America biosimulation market, by country, 2017 - 2030 (USD Million)
• Table 53 Latin America biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 54 Latin America biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 55 Latin America biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 56 Latin America biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 57 Brazil biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 58 Brazil biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 59 Brazil biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 60 Brazil biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 61 Mexico biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 62 Mexico biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 63 Mexico biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 64 Mexico biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 65 MEA biosimulation market, by country, 2017 - 2030 (USD Million)
• Table 66 MEA biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 67 MEA biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 68 MEA biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 69 MEA biosimulation market, by end-use, 2017 - 2030 (USD Million)
• Table 70 South Africa biosimulation market, by product, 2017 - 2030 (USD Million)
• Table 71 South Africa biosimulation services market, by type, 2017 - 2030 (USD Million)
• Table 72 South Africa biosimulation market, by application, 2017 - 2030 (USD Million)
• Table 73 South Africa biosimulation market, by end-use, 2017 - 2030 (USD Million)

List of Figures

• Fig. 1 Biosimulation market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Commodity Flow Analysis
• Fig. 9 Biosimulation Market outlook (2021, USD Million)
• Fig. 10 Biosimulation market segmentation and scope
• Fig. 11 Biosimulation market dynamics analysis
• Fig. 12 Biosimulation market driver and restraints impact analysis
• Fig. 13 Biosimulation market driver analysis
• Fig. 14 Biosimulation market drivers impact analysis
• Fig. 15 R&D expenditures by various market players in 2021 (USD Million)
• Fig. 16 Biosimulation market restraint impact
• Fig. 17 Biosimulation market restraint impact analysis
• Fig. 18 Penetration & growth prospect mapping
• Fig. 19 COVID-19 new cases in major 35 countries around the world
• Fig. 20 Biosimulation market: Product movement analysis
• Fig. 21 Biosimulation market product outlook: Key takeaways
• Fig. 22 Software market, 2017 - 2030 (USD Million)
• Fig. 23 Services market, 2017 - 2030 (USD Million)
• Fig. 24 In-house Services market, 2017 - 2030 (USD Million)
• Fig. 25 Contract Services market, 2017 - 2030 (USD Million)
• Fig. 26 Biosimulation market: Application movement analysis
• Fig. 27 Biosimulation market application outlook: Key takeaways
• Fig. 28 Drug development market, 2017 - 2030 (USD Million)
• Fig. 29 Drug discovery market, 2017 - 2030 (USD Million)
• Fig. 30 Others market, 2017 - 2030 (USD Million)
• Fig. 31 Biosimulation market: End-use movement analysis
• Fig. 32 Biosimulation market end-use outlook: Key takeaways
• Fig. 33 Pharmaceutical & biotechnology companies market, 2017 - 2030 (USD Million)
• Fig. 34 CROs market, 2017 - 2030 (USD Million)
• Fig. 35 Regulatory authorities market, 2017 - 2030 (USD Million)
• Fig. 36 Academic research institutions market, 2017 - 2030 (USD Million)
• Fig. 37 Regional outlook, 2021 & 2030
• Fig. 38 Regional marketplace: Key takeaways
• Fig. 39 North America Biosimulation market share, by country, 2021
• Fig. 40 U.S. biosimulation market, 2017 - 2030 (USD Million)
• Fig. 41 Canada biosimulation market, 2017 - 2030 (USD Million)
• Fig. 42 Europe biosimulation market share analysis, by country, 2021
• Fig. 43 U.K. Biosimulation market, 2017 - 2030 (USD Million)
• Fig. 44 Germany biosimulation market, 2017 - 2030 (USD Million)
• Fig. 45 France biosimulation market, 2017 - 2030 (USD Million)
• Fig. 46 Asia Pacific biosimulation market share analysis, by country, 2021
• Fig. 47 Japan biosimulation market, 2017 - 2030 (USD Million)
• Fig. 48 China biosimulation market, 2017 - 2030 (USD Million)
• Fig. 49 India biosimulation market, 2017 - 2030 (USD Million)
• Fig. 50 Latin America Biosimulation market share analysis, by country, 2021
• Fig. 51 Brazil biosimulation market, 2017 - 2030 (USD Million)
• Fig. 52 Mexico Biosimulation market, 2017 - 2030 (USD Million)
• Fig. 53 MEA biosimulation market share analysis, by country, 2021
• Fig. 54 South Africa biosimulation market, 2017 - 2030 (USD Million)
• Fig. 55 Strategy framework
• Fig. 56 Market participant categorization
• Fig. 57 Biosimulation: Heat Map Analysis
• Fig. 58 Biosimulation market: Application-wise product ranking